Denali Therapeutics (DNLI) Liabilities and Shareholders Equity (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed 0.42% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (down 17.3% YoY) and the FY2025 annual result came in at $1.1 billion, down 16.69% from the prior year.
• Liabilities and Shareholders Equity improved to $1.3 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q1 2024 and bottomed at $1.1 billion in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.3 billion (2022), against an average of $1.3 billion.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity increased 19.09%; it then slipped 27.4% in 2025.
• Tracing DNLI's Liabilities and Shareholders Equity over 5 years: stood at $1.5 billion in 2022, then dropped by 20.98% to $1.2 billion in 2023, then advanced by 19.09% to $1.4 billion in 2024, then decreased by 16.69% to $1.1 billion in 2025, then increased by 10.58% to $1.3 billion in 2026.
• Per Business Quant, the three latest DNLI Liabilities and Shareholders Equity figures stand at $1.3 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025).

Peer Comparison